27th Jan 2015 14:09
GlaxoSmithKline plc (the "Company")
Board Committee changes
GSK announces that Sir Philip Hampton has been appointed Chairman of the Nominations Committee (the "Committee") with effect from today, replacing Sir Christopher Gent, who will continue to serve as a member of the Committee for the remainder of his tenure on the Board.
In addition, Ms Lynn Elsenhans has also been appointed a member of the Committee, effective today.
The membership of the Nominations Committee is now:
Committee Chairman
| Sir Philip Hampton | Chairman Designate |
Members | Sir Christopher Gent | Chairman |
Professor Sir Roy Anderson | Scientific & Medical Expert | |
Lynn Elsenhans | Independent Non Executive Director | |
Judy Lewent | Audit & Risk Committee Chairman | |
Sir Deryck Maughan | Senior Independent Director | |
Tom de Swaan | Remuneration Committee Chairman |
V A Whyte
Company Secretary
27 January 2015
Related Shares:
Glaxosmithkline